TITLE

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

AUTHOR(S)
Grima, Daniel T.; Brown, Stephen T.; Kamboj, Laveena; Bainey, Kevin R.; Goeree, Ron; Oh, Paul; Ramanathan, Krishnan; Goodman, Shaun G.
PUB. DATE
January 2014
SOURCE
ClinicoEconomics & Outcomes Research;2014, Vol. 6, p49
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Ticagrelor demonstrated a significant reduction in major cardiac events in patients with acute coronary syndrome (ACS) compared with clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The objective of this study was to assess the cost-effectiveness of ticagrelor compared with clopidogrel in ACS patients from the perspective of the Canadian publicly funded health care system. Methods: A two-part model was developed consisting of a 1-year decision tree and a lifetime Markov model. Within the decision tree, patients remained event-free, experienced a nonfatal myocardial infarction, a nonfatal stroke, or death due to vascular or nonvascular related causes based on data from the PLATO trial. The lifetime Markov model followed these patients and allowed for subsequent myocardial infarction, stroke, and death. Patient utility and resource use were derived from the PLATO trial. Transition probabilities and specific Canadian unit costs were derived from published sources. Univariate and probabilistic sensitivity analyses were conducted. Results: In the base case lifetime analysis, treatment with ticagrelor resulted in more years of life per person (0.097), more quality-adjusted life years per person (QALYs, 0.084), and an incremental cost per QALY gained of $9,745 (Canadian$), assuming a generic cost for clopidogrel. A probabilistic sensitivity analysis demonstrated the robustness of the base case analysis, with a 93% probability of being below $20,000 per QALY gained and a 99% probability of being below $30,000 per QALY gained. Conclusion: Ticagrelor is a clinically superior and cost-effective option for the prevention of thrombotic events among ACS patients in Canada.
ACCESSION #
94750512

 

Related Articles

  • Ticagrelor good value for money in ACS in Canada.  // PharmacoEconomics & Outcomes News;Feb2014, Vol. 696 Issue 1, p8 

    The article discusses the study "Cost-Effectiveness of Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes in Canada" published in the January 24, 2014 issue of "ClinicoEconomics and Outcomes Research" which focused on the use of ticagrelor in managing acute coronary syndromes.

  • Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome. Parthan, Anju; Leahy, Kevin; O'Sullivan, Amy; Iakoubova, Olga; Bare, Lance; Devlin, James; Weinstein, Milton // PharmacoEconomics;Jun2013, Vol. 31 Issue 6, p519 

    Background: Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy...

  • Ticagrelor worth it vs clopidogrel, but watch for dyspnoea.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p11 

    The article deals with two studies on the cost effectiveness of using the antiplatelet therapy ticagrelor for the treatment of acute coronary syndrome (ACS), presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. In the first...

  • A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. Ran Xiong; Wenxian Liu; Liying Chen; Tieduo Kang; Shangqiu Ning; Jiang Li // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 8, p13310 

    Background: Compared with non-reversible, indirect P2Y12 inhibitor clopidogrel, ticagrelor is a reversible, direct acting inhibitor. The CYP2C19*2 allele is a common genetic variant in individuals that need given higher clopidogrel in acute coronary syndrome patients. Objective: We aimed to...

  • Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. Kazi, Dhruv S.; Garber, Alan M.; Shah, Rashmee U.; Adams Dudley, R.; Mell, Matthew W.; Rhee, Ceron; Moshkevich, Solomon; Boothroyd, Derek B.; Owens, Douglas K.; Hlatky, Mark A. // Annals of Internal Medicine;2/18/2014, Vol. 160 Issue 4, p221 

    Background: The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available....

  • Antiplatelet Therapy in Women With Acute Coronary Syndrome. Foody, JoAnne // Journal of Family Practice;Feb2014 Supplement, Vol. 63, pS3 

    The article focuses on the use of antiplatelet agents, prasugrel and clopidogrel, for acute coronary syndrome (ACS) treatment and the differences between women and men in safety and efficacy of those agents. Topics discussed include ACS gender-related differences, antiplatelet agents clinical...

  • Topiramate heads off migraine, elevates HRQOL. Salmon, Kimberley // PharmacoEconomics & Outcomes News;5/21/2005, Issue 478, p3 

    Provides information on several studies which examined the burden of migraine on patients, and the effect of topiramate on patients' quality of life, presented at the 57th Annual Meeting of the American Academy of Neurology in Miami Beach, Florida in April 2005. Areas of patient's life that are...

  • Did PLATO foresee the cost effectiveness of ticagrelor in ACS?  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p3 

    The article discusses research on the cost effectiveness of treating acute coronary syndrome patients with ticagrelor, referencing a study by E. Nikolic and colleagues published in the June 19, 2012 issue of the "European Heart Journal."

  • Genetic testing good to guide thienopyridine treatment.  // PharmacoEconomics & Outcomes News;10/13/2012, Issue 664, p9 

    The article discusses research on the cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes, referencing a study by L. Panattoni and colleagues.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics